Exercise in Adverse Cardiac Remodeling: of Mice and Men

Size: px
Start display at page:

Download "Exercise in Adverse Cardiac Remodeling: of Mice and Men"

Transcription

1 Exercise in Adverse Cardiac Remodeling: of Mice and Men Dirk J Duncker Experimental Cardiology, Cardiology, Thoraxcenter Cardiovascular Research Institute COEUR Erasmus MC, University Medical Center Rotterdam Rotterdam, The Netherlands

2 Cardiac Remodeling hart Normal Infarction Remodeling Heart Failure Left Ventricle

3 Cardiac Remodeling Myocardial Infarction Aortic Stenosis Physical Exercise Left Ventricular Remodeling Perfusion Function Perfusion Function Physical Exercise

4 Exercise in Adverse Cardiac Remodeling Exercise in Chronic Heart Failure - Evidence - Mechanism(s) of Action Exercise and Acute Myocardial Infarction - Evidence - Mechanism(s) of Action Exercise during Pressure Overload

5 Exercise in Adverse Cardiac Remodeling Exercise in Chronic Heart Failure - Evidence - Mechanism(s) of Action Exercise and Acute Myocardial Infarction - Evidence - Mechanism(s) of Action Exercise during Pressure Overload

6 Exercise Training in Chronic Heart Failure AJ Coats Nat Rev Cardiol 2011

7 JAMA 2009;301: All-Cause Death or Hospitalization CV Death or / HF Hospitalization

8 Exercise Training in Chronic Heart Failure ESC Guidelines May 2012 McMurray et al. Eur Heart J 2012

9 Exercise in Adverse Cardiac Remodeling Exercise in Chronic Heart Failure - Evidence - Mechanism(s) of Action Exercise and Acute Myocardial Infarction - Evidence - Mechanism(s) of Action Exercise during pressure overload

10 Exercise Training in Chronic Heart Failure Mechanisms of Action Peripheral Training Effects - skeletal muscle adaptations Cardiovascular Training Effects - Increased dynamic heart rate range Interaction With Adverse Cardiac Remodeling and Dysfunction Benito & Nattel J Physiol 2009

11 Cardiac Remodeling Myocardial Infarction Aortic Stenosis Physical Exercise Left Ventricular Remodeling Perfusion Function Perfusion Function

12 Exercise in Adverse Cardiac Remodeling Exercise in Chronic Heart Failure - Evidence - Mechanism(s) of Action Exercise and Acute Myocardial Infarction - Evidence - Mechanism(s) of Action Exercise during pressure overload

13 Cardiac Remodeling and Dysfunction Exercise training early after a large MI may aggravate cardiac remodeling and dysfunction Jugdutt et al. JACC 1988 Kubo et al. Am Heart J 2004 Kloner et al. Am Heart J 1983 Gaudron et al. Circulation 1994

14 Mouse Models of Cardiac Remodeling Myocardial infarction 8 wk Myocardial Infarction (MI) permanent LAD coronary artery ligation 45% of the LV becomes infarcted Pressure overload 8 wk Transverse Aorta Constriction (TAC)

15 Exercise 10 Distance (km) Weeks SHEX MIEX de Waard et al Circ Res 2007

16 Methods Echography Left Ventricular (LV) dimensions FS FS = LVD ED-LVD ES LVD ED X 100%

17 Methods Hemodynamics 120 Pressure (mmhg) AoP LV dp/dt (mmhg/s) LVP Time (s) Time (s)

18 Results Pressure Diameter Loop

19 Left Ventricular Pressure-Diameter Relation LV Pressure (mmhg) LV Pressure (mmhg) Sham MI SHAM MI TAC LV LV Diameter diameter (mm)

20 LV Remodeling after MI Sham MI de Waard et al. Circ Res 2007

21 Pressure-Volume relation Pressure (mmhg) MI EX SH EX 0 SH SED MI SED Diameter (mm) de Waard et al. Circ Res 2007

22 Exercise and LV Dysfunction and Remodeling after MI Wildtype Wildtype SED EX de Waard et al Circ Res 2007

23 Exercise and Cardiac Remodeling after MI End-Diastolic Volume Haykowsky et al. Trials 2011

24 Exercise and Cardiac Remodeling after MI Ejection Fraction Haykowsky et al. Trials 2011

25 Conclusions Exercise training starting early after a large MI blunts cardiac remodeling and dysfunction What are the cellular mechanisms underlying the effects of exercise training on function?

26 Exercise and LV Dysfunction and Remodeling after MI Wildtype Wildtype SED EX de Waard et al Circ Res 2007

27 Sham MI Ca 2+ Ca 2+ Ca 2+ Ca 2+ channel Noradrenaline b - AR g b a P s b - ARK camp AC ATP Sarcolemma g a i b Ca 2+ Ca 2+ Ca 2+ Ca 2+ SERCA PLB SR PKA ser P T - tubule Ca 2+ channel Tn - C P Tn - I Tn - T MI MI SED SED actin filament Ca 2+ MI EX MI EX tropomyosin myosin filament de Waard et al Circ Res 2007; Bito et al Cardiovasc Res 2010

28 A 25 B 25 Force (kn/m 2 ) C Ca Ca Ca 2+ Ca Ca 2+ Ca 2+ Ca 2+ Ca 2+ channel 5.5 pca Noradrenaline b - AR g b a P s b - ARK SH SED camp 5.0 SERCA PLB P<0.05 MI SED 4.5 SR AC PKA Force (kn/m 2 ) D ATP Sarcolemma g a i b pca 5.0 SH SED MI SED SH EX MI EX 4.5 Relative Force T - tubule pca 50 = ± Ca 2+ channel 6.0 Ca ser P SH SED MI SED 4.5 Relative Force Tn - C P Tn - I Tn - T pca myosin filament actin filament 5.0 SH SED MI SED SH EX MI EX tropomyosin 4.5 de Waard et al Circ Res 2007

29 Conclusions Exercise training after a large MI attenuates global left ventricular dysfunction This occurs likely as a result of decreased: - interstitial fibrosis - apoptosis - cardiomyocyte dysfunction What are the molecular mechanisms underlying these beneficial effects of exercise training?

30 Molecular Mechanisms of Cardiac Remodeling Mudd & Kass Nature 2008

31 Cardiac Remodeling by Exercise Training Mann & Rosenzweig Circulation 2012

32 enos transgenic mice van Haperen et al. J Biol Chem 2002 Jones et al. PNAS 2003

33 Exercise and LV Dysfunction and Remodeling after MI Endothelial Nitric Oxide Synthase Overexpression LV Hypertrophy Fibrosis LV dp/dt P30 % Shortening Jones et al. PNAS 2003; de Waard et al. Am J Physiol 2009

34 Conclusions Exercise training attenuates interstitial fibrosis, apoptosis, and cardiomyocyte and global left ventricular dysfunction after MI de Waard et al Circ Res 2007 These effects of exercise are mimicked, in part, by enos overexpression Jones et al PNAS 2003 de Waard et al Am J Physiol 2009

35 de Waard et al J Mol Cell Cardiol 2010 Exercise and LV Dysfunction and Remodeling after MI Endothelial Nitric Oxide Synthase knockout Wildtype Wildtype SED EX *P<0.05 vs Sham P<0.05 vs SED P<0.05 vs Wildtype

36 Conclusions Exercise training attenuates interstitial fibrosis, apoptosis, and cardiomyocyte and global left ventricular dysfunction after MI de Waard et al Circ Res 2007 These effects of exercise are mimicked, in part, by enos overexpression Jones et al PNAS 2003 de Waard et al Am J Physiol 2009 These effects of training appear to be fully dependent on intact enos expression de Waard et al J Mol Cell Cardiol 2010

37 Exercise in Adverse Cardiac Remodeling Exercise in Chronic Heart Failure - Evidence - Mechanism(s) of Action Exercise and Acute Myocardial Infarction - Evidence - Mechanism(s) of Action Exercise during pressure overload

38 Mouse Models of Cardiac Remodeling Myocardial infarction 8 wk Myocardial Infarction (MI) permanent LAD coronary artery ligation Pressure overload 8 wk Transverse Aorta Constriction (TAC) mtac: 25G stac: 27G 37± 3 mmhg 57± 4 mmhg

39 Effects of exercise in TAC versus MI % Shortening Filling Pressure Fibrosis Lung Edema Maximum Force Passive Force Ca 2+ Sensitivity SERCA Van Deel et al J Mol Cell Cardiol 2011

40 Conclusions The effects of exercise training on left ventricular dysfunction appear critically dependent on the underlying cause of hypertrophy / remodeling These divergent effects may be due to intrinsic differences in the remodeling phenotype or the different hemodynamic responses to exercise enos overexpression: The benefit of exercise without the hemodynamic overloading?

41 Mann & Rosenzweig Circulation 2012

42 Acknowledgements Erasmus University MC Rotterdam Experimental Cardiology Elza van Deel Martine de Boer Monique de Waard Ewout Jan van den Bos Biochemistry Dick Dekkers Jos Lamers Cell Biology and Genetics Rini de Crom Rien van Haperen Frank Grosveld Free University MC Amsterdam Jolanda van der Velden Nicky Boontje Ger Stienen Maastricht University An Moens Catholic University of Leuven Karin Sipido Virginie Bito Liesbeth Biesmans Emory University David Lefer Funding Netherlands Organization of Scientific Research (ZonMW / NWO) Royal Netherlands Academy of Arts and Sciences (KNAW) Netherlands Heart Foundation (NHS)

Supplemental Figure I

Supplemental Figure I Supplemental Figure I Kl ( mmol/l)-induced Force orta M (mn) 1 (mn) 1 Supplemental Figure I. Kl-induced contractions. and, Kl ( mmol/l)-induced contractions of the aorta () and those of mesenteric arteries

More information

Cardiac Gene Therapy: Beyond the Mouse. David M Kaye Heart Failure Research Group Baker IDI, Melbourne, AUSTRALIA

Cardiac Gene Therapy: Beyond the Mouse. David M Kaye Heart Failure Research Group Baker IDI, Melbourne, AUSTRALIA Cardiac Gene Therapy: Beyond the Mouse David M Kaye Heart Failure Research Group Baker IDI, Melbourne, AUSTRALIA Presenter Disclosure Information FINANCIAL DISCLOSURE: Equity: Osprey Medical Grants/Research

More information

In Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison

In Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison In Vivo Animal Models of Heart Disease Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison Why Animal Models of Disease? Heart Failure (HF) Leading cause of morbidity and mortality

More information

Alterations in cardiomyocyte function during diastolic heart failure

Alterations in cardiomyocyte function during diastolic heart failure Alterations in cardiomyocyte function during diastolic heart failure Attila Borbély VUmc UDMHSC, Division of Clinical Physiology, Institute of Cardiology, Debrecen, Hungary Laboratory for Physiology, ICaR-VU

More information

Heart Failure with Preserved Left Ventricular Ejection Fraction. (HFpEF)

Heart Failure with Preserved Left Ventricular Ejection Fraction. (HFpEF) Thessaloniki, May 27, 2017 Heart Failure with Preserved Left Ventricular Ejection Fraction Filippos Triposkiadis, MD, FESC, FACC Professor of Cardiology Director, Department of Cardiology Larissa University

More information

Philipp Schlegel, Jan Ksienzyk, Jens Barthelmes, Uwe Haberkorn, Walter J. Koch, Hugo A. Katus, Patrick Most, Oliver J. Mueller, Philip W.J.

Philipp Schlegel, Jan Ksienzyk, Jens Barthelmes, Uwe Haberkorn, Walter J. Koch, Hugo A. Katus, Patrick Most, Oliver J. Mueller, Philip W.J. UniversityHospital Heidelberg Cardiac AAV6.betaARKct gene therapy ameliorates cardiac function and normalizes neurohumoral signaling in a clinically relevant large animal heart failure model Philipp Schlegel,

More information

1. Cardiomyocytes and nonmyocyte. 2. Extracellular Matrix 3. Vessels שאלה 1. Pathobiology of Heart Failure Molecular and Cellular Mechanism

1. Cardiomyocytes and nonmyocyte. 2. Extracellular Matrix 3. Vessels שאלה 1. Pathobiology of Heart Failure Molecular and Cellular Mechanism Pathobiology of Heart Failure Molecular and Cellular Mechanism Jonathan Leor Neufeld Cardiac Research Institute Tel-Aviv University Sheba Medical Center, Tel-Hashomer שאלה 1 התא הנפוץ ביותר (75%~) בלב

More information

Exploring the Reno-Cardiac Connection. Protect your kidneys save your heart

Exploring the Reno-Cardiac Connection. Protect your kidneys save your heart Exploring the Reno-Cardiac Connection Protect your kidneys save your heart Heart Failure: a major health care problem ~23 million people with heart failure worldwide Heart failure increases progressively

More information

Pathophysiology and Diagnosis of Heart Failure

Pathophysiology and Diagnosis of Heart Failure Pathophysiology and Diagnosis of Heart Failure Francesco Paneni, MD, PhD, FESC Cardiology Unit Karolinska University Hospital Stockholm, Sweden Cardiology University Hospital Zurich Switzerland francesco.paneni@gmail.com

More information

Ventricular Interactions in the Normal and Failing Heart

Ventricular Interactions in the Normal and Failing Heart Ventricular Interactions in the Normal and Failing Heart Congenital Cardiac Anesthesia Society 2015 Pressure-volume relations Matched Left ventricle to low hydraulic impedance Maximal stroke work limited

More information

How does Exercise Work at the Cellular/Molecular Level

How does Exercise Work at the Cellular/Molecular Level How does Exercise Work at the Cellular/Molecular Level Volker Adams, PhD ESC, Paris 28. Aug. 211 UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Nothing to disclose Survival Exercise Training in Patients With

More information

Mimecan and cardiac extracellular matrix integrity Lucas Van Aelst, MD Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium

Mimecan and cardiac extracellular matrix integrity Lucas Van Aelst, MD Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium Mimecan and cardiac extracellular matrix integrity Lucas Van Aelst, MD Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium VIB-Vesalius Research Center, KULeuven, Leuven, Belgium

More information

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect

More information

Outline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies

Outline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the

More information

The Cardiovascular System and Aging- Is it Built to Fail?

The Cardiovascular System and Aging- Is it Built to Fail? The Cardiovascular System and Aging- Is it Built to Fail? Francis G. Spinale, MD, PhD Professor of Surgery and Cell Biology and Anatomy University of South Carolina School of Medicine Veterans Affairs

More information

New drugs on the horizon for heart failure: CaMK antagonists

New drugs on the horizon for heart failure: CaMK antagonists New drugs on the horizon for heart failure: CaMK antagonists (Lars S. Maier) Gerd Hasenfuss Disclosure Information: No relationship exists related to this presentation Dept. of Cardiology and Pneumology,

More information

Pathophysiology: Heart Failure

Pathophysiology: Heart Failure Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions

More information

CNS Effects of Aldosterone :

CNS Effects of Aldosterone : CNS Effects of Aldosterone : Critical Roles in salt-sensitive sensitive hypertension and CHF. Frans HH Leenen MD, PhD, FRCPC, FAHA 2 Renin Angiotensin Aldosterone System Circulatory RAAS Tissue RAAS: -

More information

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension In the name of GOD Animal models of cardiovascular diseases: myocardial infarction & hypertension 44 Presentation outline: Cardiovascular diseases Acute myocardial infarction Animal models for myocardial

More information

Aortic valve Stenosis: Insights in the evaluation of LV function. Erwan DONAL Cardiologie CHU Rennes

Aortic valve Stenosis: Insights in the evaluation of LV function. Erwan DONAL Cardiologie CHU Rennes Aortic valve Stenosis: Insights in the evaluation of LV function Erwan DONAL Cardiologie CHU Rennes erwan.donal@chu-rennes.fr Preload Afterload Myocardial Fiber Shortening Circumferential Longitudinal

More information

Diabetes and the Heart

Diabetes and the Heart Diabetes and the Heart Association of Specialty Professors April 4, 2013 Jorge Plutzky, MD Co-Director, Preventive Cardiology Director, The Lipid Clinic Cardiovascular Division Brigham and Women s Hospital

More information

BEDSIDE ASSESSMENT OF PATIENTS WITH STEMI

BEDSIDE ASSESSMENT OF PATIENTS WITH STEMI BEDSIDE ASSESSMENT OF PATIENTS WITH STEMI Prof. Maria Dorobantu, PhD, FESC, FACC Emergency Hospital of Bucharest, Romania Presenter Disclosures There are no conflicts/ grants/ disclosures for this presentation.

More information

Small Platform Catheter-Based Left Ventricular Assist Device Support Suppresses Cardioprotective Beta Arrestin- Mediated Signal Transduction

Small Platform Catheter-Based Left Ventricular Assist Device Support Suppresses Cardioprotective Beta Arrestin- Mediated Signal Transduction Small Platform Catheter-Based Left Ventricular Assist Device Support Suppresses Cardioprotective Beta Arrestin- Mediated Signal Transduction Keshava Rajagopal, MD PhD, Progyaparamita Saha, PhD, Isa Mohammed,

More information

International Graduate Research Programme in Cardiovascular Science

International Graduate Research Programme in Cardiovascular Science 1 International Graduate Research Programme in Cardiovascular Science This work has been supported by the European Community s Sixth Framework Programme under grant agreement n LSHM-CT-2005-01883 EUGeneHeart.

More information

The right heart: the Cinderella of heart failure

The right heart: the Cinderella of heart failure The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart

More information

Yokohama City University School of Medicine Susumu Minamisawa (

Yokohama City University School of Medicine Susumu Minamisawa ( Yokohama City University School of Medicine Susumu Minamisawa ( skeletal muscle cardiac muscle mitochondria Sarcoplasmic reticulum mitochondria I A T-tubule SR Free Ca 2+ T-tubule SR Opi. The Heart, 3rd

More information

Mechanisms of heart failure with normal EF Arterial stiffness and ventricular-arterial coupling. What is the pathophysiology at presentation?

Mechanisms of heart failure with normal EF Arterial stiffness and ventricular-arterial coupling. What is the pathophysiology at presentation? Mechanisms of heart failure with normal EF Arterial stiffness and ventricular-arterial coupling What is the pathophysiology at presentation? Ventricular-arterial coupling elastance Central arterial pressure

More information

Η ηχωκαρδιολογία στην διάγνωση κα πρόγνωση της καρδιακής ανεπάρκειας µε µειωµένο και φυσιολογικό κλάσµα εξώθησης

Η ηχωκαρδιολογία στην διάγνωση κα πρόγνωση της καρδιακής ανεπάρκειας µε µειωµένο και φυσιολογικό κλάσµα εξώθησης Η ηχωκαρδιολογία στην διάγνωση κα πρόγνωση της καρδιακής ανεπάρκειας µε µειωµένο και φυσιολογικό κλάσµα εξώθησης Βασίλειος Σαχπεκίδης Επιµελητής Β Καρδιολογίας Γ.Ν. Παπαγεωργίου Θεσσαλονίκη ESC Guidelines

More information

The Journal of Physiology

The Journal of Physiology J Physiol 589.5 (2011) pp 1037 1045 1037 TOPICAL REVIEW Integrative Physiology 2.0 : integration of systems biology into physiology and its application to cardiovascular homeostasis Diederik W. D. Kuster

More information

Fetal gene upregulation by 1-wk TAC is significantly increased in mice lacking RGS2.

Fetal gene upregulation by 1-wk TAC is significantly increased in mice lacking RGS2. 3562-RG-1 Supplementary Figure 1 Fetal gene upregulation by 1-wk is significantly increased in mice lacking RGS2. ANP(Nppa) /BNP(Nppb) A-type and B-type natriuretic peptide; β-mhc (Myh7) beta myosin heavy

More information

Diagnosis is it really Heart Failure?

Diagnosis is it really Heart Failure? ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University

More information

Counterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece

Counterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87

More information

LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital

LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital LV inflow across MV LV LV outflow across AV LV LV geometric changes Pressure overload

More information

Evalua&on)of)Le-)Ventricular)Diastolic) Dysfunc&on)by)Echocardiography:) Role)of)Ejec&on)Frac&on)

Evalua&on)of)Le-)Ventricular)Diastolic) Dysfunc&on)by)Echocardiography:) Role)of)Ejec&on)Frac&on) Evalua&on)of)Le-)Ventricular)Diastolic) Dysfunc&on)by)Echocardiography:) Role)of)Ejec&on)Frac&on) N.Koutsogiannis) Department)of)Cardiology) University)Hospital)of)Patras)! I have no conflicts of interest

More information

Remodeling the failing heart: : the biology and future treatment options

Remodeling the failing heart: : the biology and future treatment options Remodeling the failing heart: : the biology and future treatment options J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be Myocardial remodeling: definitions phenotypic plasticity : remodeling

More information

Tcf21 MCM ; R26 mtmg Sham GFP Col 1/3 TAC 8W TAC 2W. Postn MCM ; R26 mtmg Sham GFP Col 1/3 TAC 8W TAC 2W

Tcf21 MCM ; R26 mtmg Sham GFP Col 1/3 TAC 8W TAC 2W. Postn MCM ; R26 mtmg Sham GFP Col 1/3 TAC 8W TAC 2W A Tcf21 MCM ; R26 mtmg Sham GFP Col 1/3 Tcf21 MCM ; R26 mtmg TAC 2W Tcf21 MCM ; R26 mtmg TAC 8W B Postn MCM ; R26 mtmg Sham GFP Col 1/3 Postn MCM ; R26 mtmg TAC 2W Postn MCM ; R26 mtmg TAC 8W Supplementary

More information

Constrictive/Restrictive Cardiomyopathies: Diagnosis and Management Update; Radiation Induced Heart Disease. Alexander (Sandy) Dick, MD

Constrictive/Restrictive Cardiomyopathies: Diagnosis and Management Update; Radiation Induced Heart Disease. Alexander (Sandy) Dick, MD Constrictive/Restrictive Cardiomyopathies: Diagnosis and Management Update; Radiation Induced Heart Disease Alexander (Sandy) Dick, MD Outline Pericardial Constriction Diagnosis: Imaging, Hemodynamics

More information

Control of Myocardial Blood Flow

Control of Myocardial Blood Flow Control of Myocardial Blood Flow Blood goes where it is needed John Hunter, 1794 Cited by Dunker DJ and Bache RJ Physiol Rev, 2008 Bernard De Bruyne, MD, PhD Cardiovascular Center Aalst OLV-Clinic Aalst,

More information

Management of the coronary patient in Roberto Ferrari

Management of the coronary patient in Roberto Ferrari Management of the coronary patient in 2011 Roberto Ferrari What is new in treatment of stable CAD? In the era of interventional cardiology, is chronic stable angina a rare disease? Stable angina pectoris

More information

Supplementary Figure 1. Confocal immunofluorescence showing mitochondrial translocation of Drp1. Cardiomyocytes treated with H 2 O 2 were prestained

Supplementary Figure 1. Confocal immunofluorescence showing mitochondrial translocation of Drp1. Cardiomyocytes treated with H 2 O 2 were prestained Supplementary Figure 1. Confocal immunofluorescence showing mitochondrial translocation of Drp1. Cardiomyocytes treated with H 2 O 2 were prestained with MitoTracker (red), then were immunostained with

More information

Load and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic

Load and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic Load and Function - Valvular Heart Disease Tom Marwick, Cardiovascular Imaging Cleveland Clinic Indications for surgery in common valve lesions Risks Operative mortality Failed repair - to MVR Operative

More information

Uncovering the mechanisms of wound healing and fibrosis

Uncovering the mechanisms of wound healing and fibrosis Any Questions??? Ask now or contact support support@sabiosciences.com 1-888-503-3187 International customers: SABio@Qiagen.com Uncovering the mechanisms of wound healing and fibrosis Webinar related questions:

More information

LXIV: DRUGS: 4. RAS BLOCKADE

LXIV: DRUGS: 4. RAS BLOCKADE LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations

More information

LA Function analysis Marcia Barbosa Vice Presidente - Brazilian Soc of Cardiology President-elect - Interamerican Soc of Cardiology

LA Function analysis Marcia Barbosa Vice Presidente - Brazilian Soc of Cardiology President-elect - Interamerican Soc of Cardiology LA Function analysis Marcia Barbosa Vice Presidente - Brazilian Soc of Cardiology President-elect - Interamerican Soc of Cardiology Belo Horizonte Brazil DECLARATION OF CONFLICT OF INTEREST Nothing to

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Disclosures: Research grants & clinical trials (Gilead), honoraria & clinical trials (Berlin-Chemie/Menarini) Ranolazine in Heart Failure with Preserved Ejection Fraction

More information

LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION

LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION Jamilah S AlRahimi Assistant Professor, KSU-HS Consultant Noninvasive Cardiology KFCC, MNGHA-WR Introduction LV function assessment in Heart Failure:

More information

Assessing the Impact on the Right Ventricle

Assessing the Impact on the Right Ventricle Advances in Tricuspid Regurgitation Congress of the European Society of Cardiology (ESC) Munich, August 25-29, 2012 Assessing the Impact on the Right Ventricle Stephan Rosenkranz, MD Clinic III for Internal

More information

Heart Failure: The Frequent, Forgotten and often Fatal Complication of Type 2 Diabetes

Heart Failure: The Frequent, Forgotten and often Fatal Complication of Type 2 Diabetes Heart Failure: The Frequent, Forgotten and often Fatal Complication of Type 2 Diabetes DAVID S. H. BELL CHAIRMAN BELL, DSH. DIABETES CARE(2003)26:2433-41. Speaker s Bureau: AstraZeneca Novo Nordisk Janssen

More information

Index. A Action potential duration, increased, by decreases in sodium current,

Index. A Action potential duration, increased, by decreases in sodium current, Heart Failure Clin 1 (2005) 313 319 Index Note: Page numbers of article titles are in boldface type. A Action potential duration, increased, by decreases in sodium current, 201 202 Adenylyl cyclase, overexpression

More information

Muscle Cells & Muscle Fiber Contractions. Packet #8

Muscle Cells & Muscle Fiber Contractions. Packet #8 Muscle Cells & Muscle Fiber Contractions Packet #8 Skeletal muscle is attached to bones and is responsible for movement. Introduction Introduction II Skeletal muscle is composed of bundles of muscle fibers

More information

Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies

Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern

More information

Diastolic Heart Failure (HFpEF) Felix J. Rogers, DO, FACOI April 29, 2018

Diastolic Heart Failure (HFpEF) Felix J. Rogers, DO, FACOI April 29, 2018 Diastolic Heart Failure (HFpEF) Felix J. Rogers, DO, FACOI April 29, 2018 Case presentation MSO, an 81 year old woman was admitted to HFWH because of progressive dyspnea and difficult to control hypertension

More information

Nox-Dependent Mechanisms of Cardiomyocyte Dysfunction in a Model of Pressure Overload

Nox-Dependent Mechanisms of Cardiomyocyte Dysfunction in a Model of Pressure Overload Nox-Dependent Mechanisms of Cardiomyocyte Dysfunction in a Model of Pressure Overload Giovanna Frazziano, PhD Vascular Medicine Institute Department of Pharmacology and Chemical Biology University of Pittsburgh

More information

Gene Transfer During LVAD Support. University of Pittsburgh Medical Center Pittsburgh, PA

Gene Transfer During LVAD Support. University of Pittsburgh Medical Center Pittsburgh, PA Gene Transfer During LVAD Support University of Pittsburgh Medical Center Pittsburgh, PA Heart Failure Major cause of morbidity and mortality In the United States each year, more than 1,000,000 hospitalizations

More information

Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy Hypertrophic Cardiomyopathy From Genetics to ECHO Alexandra A Frogoudaki Second Cardiology Department ATTIKON University Hospital Athens University Athens, Greece EUROECHO 2010, Copenhagen, 11/12/2010

More information

Patient-specific modeling of heart and circulation

Patient-specific modeling of heart and circulation Patient-specific modeling of heart and circulation Theo Arts t.arts@bf.unimaas.nl Maastricht University, *Maastricht University Hospital **University of Tecnology, Eindhoven The Netherlands *Tammo Delhaas,

More information

Heart Failure Treatment In Patients With Recurrent Myocardial Infarction

Heart Failure Treatment In Patients With Recurrent Myocardial Infarction Received: 10-01-2013 Accepted: 19-02-2013 ISSN: 2277-7695 CODEN Code: PIHNBQ ZDB-Number: 2663038-2 IC Journal No: 7725 Vol. 2 No. 1 2013 Online Available at www.thepharmajournal.com THE PHARMA INNOVATION

More information

Antialdosterone treatment in heart failure

Antialdosterone treatment in heart failure Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition

More information

MCD-microRNA. WU Hong-quan, LIU Di-chuan *, TONG Xin, CAI Min, HUANG Jing. (LVIDd) A [ ] (2012)

MCD-microRNA. WU Hong-quan, LIU Di-chuan *, TONG Xin, CAI Min, HUANG Jing. (LVIDd) A [ ] (2012) MCD-microRNA [ ] A (MCD)-microRNA MCD MCD 4 MCD-microRNA HEK293 PCR MCD mrna 28 + 3 ( + + + + + + ) 7 7 ( + ) MCD-microRNA 4 4d 1 28d (LVEF) (FS) (LVIDd)A PCR 1 MCD mrna82% + + + LVEF FS (P 0.05) (P 0.05)

More information

DIASTOLIC HEART FAILURE

DIASTOLIC HEART FAILURE DIASTOLIC HEART FAILURE M Mohsen Ibrahim, MD Alexandria, Proposed Criteria for Diastolic Heart Failure ESC Working Group (EHJ 1998) CHF signs/symptoms EF 45% Hemodynamic or echo evidence of diastolic dysfunction

More information

PHYSIOLOGY MeQ'S (Morgan) All the following statements related to blood volume are correct except for: 5 A. Blood volume is about 5 litres. B.

PHYSIOLOGY MeQ'S (Morgan) All the following statements related to blood volume are correct except for: 5 A. Blood volume is about 5 litres. B. PHYSIOLOGY MeQ'S (Morgan) Chapter 5 All the following statements related to capillary Starling's forces are correct except for: 1 A. Hydrostatic pressure at arterial end is greater than at venous end.

More information

Estrogens vs Testosterone for cardiovascular health and longevity

Estrogens vs Testosterone for cardiovascular health and longevity Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in

More information

Cardiovascular Imaging Stress Echo

Cardiovascular Imaging Stress Echo Cardiovascular Imaging Stress Echo Theodora A Zaglavara, MD, PhD Cardiac Imaging Department INTERBALKAN MEDICAL CENTER Thessaloniki GREECE Evolution of Stress Echo: From Innovation to a Widely Established

More information

Left atrial function. Aliakbar Arvandi MD

Left atrial function. Aliakbar Arvandi MD In the clinic Left atrial function Abstract The left atrium (LA) is a left posterior cardiac chamber which is located adjacent to the esophagus. It is separated from the right atrium by the inter-atrial

More information

Conflict of Interest Slide

Conflict of Interest Slide Comparison of six- month clinical outcomes, event free survival rates of patients undergoing enhanced external counterpulsation (EECP) for coronary artery disease in the United States and Europe Ozlem

More information

Microstructural Basis of Conduction II Introduction to Experimental Studies

Microstructural Basis of Conduction II Introduction to Experimental Studies Bioeng 6460 Electrophysiology and Bioelectricity Microstructural Basis of Conduction II Introduction to Experimental Studies Frank B. Sachse fs@cvrti.utah.edu Overview Microstructural Basis of Conduction

More information

Risk Stratification in Heart Failure: The Role of Emerging Biomarkers

Risk Stratification in Heart Failure: The Role of Emerging Biomarkers Risk Stratification in Heart Failure: The Role of Emerging Biomarkers David G. Grenache, PhD Associate Professor of Pathology, University of Utah Medical Director, ARUP Laboratories Salt Lake City, UT

More information

Systolic and Diastolic Dysfunction: Four Upcoming Challenges

Systolic and Diastolic Dysfunction: Four Upcoming Challenges Systolic and Diastolic Dysfunction: Four Upcoming Challenges Promoting Early Detection HFrEF: Beyond Neprilysin/Enalapril HFmrEF: What Is It and How Does One Manage It? HFpEF: Etiopathogenetic Role and

More information

Does Pharmacological Exercise Mimetics Exist? Hokkaido University Graduate School of Medicine Shintaro Kinugawa

Does Pharmacological Exercise Mimetics Exist? Hokkaido University Graduate School of Medicine Shintaro Kinugawa Does Pharmacological Exercise Mimetics Exist? Hokkaido University Graduate School of Medicine Shintaro Kinugawa Survival rate (%) Peak oxygen uptake and prognosis in patients with heart failure (HF) 1

More information

Advanced imaging of the left atrium - strain, CT, 3D, MRI -

Advanced imaging of the left atrium - strain, CT, 3D, MRI - Advanced imaging of the left atrium - strain, CT, 3D, MRI - Monica Rosca, MD Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Declaration of interest: I have nothing to declare Case

More information

Aortic Stenosis Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan

Aortic Stenosis Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Aortic Stenosis - 2011 Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Aortic Surgery Aortic Stenosis EB CT - Ca++ everywhere! Surgery for Aortic Stenosis 100,000 USA + 100,000

More information

Rationale for Prophylactic Support During Percutaneous Coronary Intervention

Rationale for Prophylactic Support During Percutaneous Coronary Intervention Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories

More information

CARDIOVASCULAR PHYSIOLOGY

CARDIOVASCULAR PHYSIOLOGY CARDIOVASCULAR PHYSIOLOGY LECTURE 5 Heart as a pump cardiac performance Coronary circulation. Particularities of the cardiac muscle metabolism. Ana-Maria Zagrean MD, PhD Chemical energy required for cardiac

More information

Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure

Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics

More information

Exercise Testing and Training in Heart Failure Patients Robert S. McKelvie, MD, PhD, FRCPC, Hamilton Health Sciences - General Division

Exercise Testing and Training in Heart Failure Patients Robert S. McKelvie, MD, PhD, FRCPC, Hamilton Health Sciences - General Division Exercise Testing and Training in Heart Failure Patients Robert S. McKelvie, MD, PhD, FRCPC, Hamilton Health Sciences - General Division Studies have demonstrated that there is no relationship between left

More information

renoprotection therapy goals 208, 209

renoprotection therapy goals 208, 209 Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization

More information

Heart Failure with Preserved Ejection Fraction: Pathologies, Aetiology and Directions for Treatment

Heart Failure with Preserved Ejection Fraction: Pathologies, Aetiology and Directions for Treatment Heart Failure with Preserved Ejection Fraction: Pathologies, Aetiology and Directions for Treatment Dr Will Watson Oxford Centre for Magnetic Resonance Research Will.watson@cardiov.ox.ac.uk Introduction

More information

Heart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output

Heart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover

More information

Cardiac hypertrophy : differentiating disease from athlete

Cardiac hypertrophy : differentiating disease from athlete Cardiac hypertrophy : differentiating disease from athlete Ario Soeryo Kuncoro, MD, Cardiologist Echocardiography Division, National Cardiovascular Centre Harapan Kita-Jakarta Departement of Cardiology

More information

Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro

Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro Jerónimo Farré MD, Madrid, ES AF: the kingdom of wishful thinking In AF we

More information

Cardiovascular Physiology. Heart Physiology. Introduction. The heart. Electrophysiology of the heart

Cardiovascular Physiology. Heart Physiology. Introduction. The heart. Electrophysiology of the heart Cardiovascular Physiology Heart Physiology Introduction The cardiovascular system consists of the heart and two vascular systems, the systemic and pulmonary circulations. The heart pumps blood through

More information

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine

More information

Genotype Positive/ Phenotype Negative: Is It a Disease?

Genotype Positive/ Phenotype Negative: Is It a Disease? Genotype Positive/ Phenotype Negative: Is It a Disease? Michelle Michels MD, PhD Center of Inherited Cardiovascular Diseases Erasmus MC, Rotterdam, the Netherlands No disclosures What is phenotype negative

More information

Fuel the Failing Heart: glucose or fatty acids? Rong Tian, MD, PhD Mitochondria and Metabolism Center University of Washington, Seattle

Fuel the Failing Heart: glucose or fatty acids? Rong Tian, MD, PhD Mitochondria and Metabolism Center University of Washington, Seattle Fuel the Failing Heart: glucose or fatty acids? Rong Tian, MD, PhD Mitochondria and Metabolism Center University of Washington, Seattle Metabolic Remodeling: Fatty Acids Carbohydrates PCr/ATP Glucose vs.

More information

There is no conflict of interests for the following presentation

There is no conflict of interests for the following presentation There is no conflict of interests for the following presentation Inflammation and Left Ventricular Diastolic Dysfunction Cho-Kai Wu MD National Taiwan University Hospital, Taipei, Taiwan Diastolic heart

More information

ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας

ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας

More information

What is established? Risk of Benefit complica comp tion

What is established? Risk of Benefit complica comp tion What s new in exercise training in CHF? Jean-Paul Schmid, MD, FESC Consultant Cardiologist, SpitalNetzBern Tiefenau Hospital, Dept. of Internal Medicine, Cardiology, Bern, Switzerland What is established?

More information

Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics

Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics Richard Sheppard MD FRCPC Director of Heart Failure Research Heart Function Clinic Jewish General hospital Objectives 1. Discuss

More information

Value of echocardiography in chronic dyspnea

Value of echocardiography in chronic dyspnea Value of echocardiography in chronic dyspnea Jahrestagung Schweizerische Gesellschaft für /Schweizerische Gesellschaft für Pneumologie B. Kaufmann 16.06.2016 Chronic dyspnea Shortness of breath lasting

More information

I have nothing to disclose.

I have nothing to disclose. I have nothing to disclose. ESC Congress, München, 2012 Pulmonary Circulation and the Right and Left Ventricles Left Ventricle in Pulmonary Hypertension Robert Naeije Erasme University Hospital Brussels,

More information

Νεότερα ςτην Υπερηχοκαρδιογραφία. Βαςίλειοσ Καμπερίδησ Clinical research fellow in Cardiology

Νεότερα ςτην Υπερηχοκαρδιογραφία. Βαςίλειοσ Καμπερίδησ Clinical research fellow in Cardiology Νεότερα ςτην Υπερηχοκαρδιογραφία Βαςίλειοσ Καμπερίδησ Clinical research fellow in Cardiology Disclosures ESC training grant EACVI research grant HCS training grant ELIKAR research grant Evolution of Echocardiography

More information

Interest of PVO2 assesment in HFpEF patients

Interest of PVO2 assesment in HFpEF patients Interest of PVO2 assesment in HFpEF patients Jean Yves TABET CRCB, Villeneuve Saint Denis Institut Jacques Cartier, Massy Conflits of interest none Interest of PVO2 in HFr EF Evaluation of exercise tolerance

More information

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University

More information

HYPERTENSION AND HEART FAILURE

HYPERTENSION AND HEART FAILURE HYPERTENSION AND HEART FAILURE Kenya Cardiac Society Symposium Feb 2017 Dr Jeilan Mohamed No conflict of interests . Geoffrey, 45 yr old hypertensive office worker male from Nairobi, has just watched his

More information

Follow-up of the CUPID Gene Therapy Trials

Follow-up of the CUPID Gene Therapy Trials Follow-up of the CUPID Gene Therapy Trials Roger J. Hajjar, MD Icahn School of Medicine at Mount Sinai New York, NY Pathway to Heart Failure Injury / Damage Mature Dysfunctional Dying New Coronary Disease

More information

Managing the Low Output Low Gradient Aortic Stenosis Patient

Managing the Low Output Low Gradient Aortic Stenosis Patient Managing the Low Output Low Gradient Aortic Stenosis Patient R A Nishimura MD Judd and Mary Leighton Professor of CV Mayo Clinic No disclosures Valvular Stenosis Severity of Aortic Stenosis Mean gradient

More information

Chapter 13 The Cardiovascular System: Cardiac Function

Chapter 13 The Cardiovascular System: Cardiac Function Chapter 13 The Cardiovascular System: Cardiac Function Overview of the Cardiovascular System The Path of Blood Flow through the Heart and Vasculature Anatomy of the Heart Electrical Activity of the Heart

More information

Probe. Hind III Q,!&#12?R'!! /0!!!!D1"?R'! vector. Homologous recombination

Probe. Hind III Q,!&#12?R'!! /0!!!!D1?R'! vector. Homologous recombination Supple-Zhang Page 1 Wild-type locus Targeting construct Targeted allele Exon Exon3 Exon Probe P1 P P3 FRT FRT loxp loxp neo vector amh I Homologous recombination neo P1 P P3 FLPe recombination Q,!&#1?R'!!

More information

Myocardial Creatinkinase as a Possible Predictor. of Myocardial Changes in Children. with Biciuspid Aortic Valve

Myocardial Creatinkinase as a Possible Predictor. of Myocardial Changes in Children. with Biciuspid Aortic Valve Biological Markers and Guided Therapy, Vol. 1, 2014, no. 2, 79-83 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/bmgt.2014.479 Myocardial Creatinkinase as a Possible Predictor of Myocardial Changes

More information